New In Vitro Eicosapentaenoic Acid Study Data to Be Presented at the National Lipid Association Scientific Sessions in Chicago

BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 06/11/15 -- Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro study at the National Lipid Association Scientific Sessions being held June 11-14 in Chicago. The study of the inhibitory effect of eicosapentaenoic acid (EPA) on the formation of cholesterol crystalline domains in model biological membranes subjected to high cholesterol levels (to simulate atherosclerotic-like conditions) indicated a level of reduction with EPA that was not reproduced with other triglyceride-lowering agents tested. The poster, titled "Eicosapentaenoic Acid (EPA), But Not Other TG-Lowering Agents, Reduces Cholesterol Domain Levels in Atherosclerotic-Like Model Membranes," will be presented at the author Q&A session scheduled for June 13, 2015 from 11:20 a.m.-12:20 p.m. CDT.

"This study was conducted in vitro using model biological membranes under conditions of hypercholesterolemia," commented Preston Mason, Ph.D., of Brigham and Women's Hospital and the study's lead investigator. "The purpose of the study was to examine whether EPA, under atherosclerotic-like conditions, can reduce the formation of cholesterol crystalline domains. Our research team found that EPA reduced cholesterol crystalline domain levels in cholesterol-enriched model membranes by 65% (p

Additional studies are needed to determine if the effects of EPA shown in this study would have clinically meaningful benefit in the human body.

This poster will be presented by Dr. R. Preston Mason, PhD, of Brigham and Women's Hospital. Dr. Mason is also the President and Founder of Elucida Research.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. For more information about Amarin visit www.amarincorp.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the potential efficacy, safety and therapeutic benefits of EPA, including statements about the potential clinical importance of the findings presented. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with in vitro research, research and development and clinical trials, including the risk that in vitro study results may not be predictive of future results or replicated in study in man and that studied parameters may not have clinically meaningful effect. A list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Investor Relations

   Michael Farrell  Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) [email protected] Morrell Trout Group   In U.S.: +1 (646) [email protected] InquiriesLee Davies Makovsky In U.S.: +1 (212) [email protected]

Source: Amarin Corp. Plc

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Cue Health Inc. (HLTH) Announces CFO Resignation
• IBM (IBM) to Acquire HashiCorp (HCP) for $35/sh Cash or $6.4B